SimpliFiH™ Solutions is specifically designed to reduce phase I timelines by at least 3 months vs traditional approaches. This service is also designed for the flexibility required to fit your molecule and drug program:

1. API to OEL 4 – dedicated kilo-labs and teams in place to provide the quantities necessary for preclinical and early clinical trials
2. Solid state characterization – API physicochemical characterization, aqueous solubility, salt and polymorph screening services
3. Solubility and solubility rate enhancement – proprietary modeling / technology selection services and manufacture of enabled phase I drug product with required dissolution rate and/or aqueous solubility
4. Drug product in phase-appropriate format: powder-in-capsule (PIC), powder-in-bottle (PIB), liquid-filled hard capsules (LFHC) or tablets

To learn more about SimpliFiH™, please download our technical brief (PDF).

Don`t forget to register for our upcoming webinars:

• Oral peptide delivery utilizing specialized encapsulation technologies by Hassan Benameur, Ph.D
• Technical considerations for capsule-based inhalation product development by Herbert Chiou, Ph.D and Salvatore Mercuri, Ph.D
• Drug Product Advancement – a path through development by powder in capsule approach by Mark Cappucci, Alyssa Botta and Rebecca Henry 
• Advances in bioavailability enhancing technologies for poorly soluble molecules:  In vitro and In vivo case studies by David Lyon, Ph.D